Table 2.
Association between neurokinin 1 receptor expression level and clinicopathological parameters.
| Parameters | Low or no expression | High expression | p |
|---|---|---|---|
| Percentage (%)/mean ± SD | Percentage (%)/mean ± SD | ||
| Age (years) | 51.94 ± 11.61 | 50.21 ± 10.41 | 0.350 |
| Molecular subtype | 0.493 | ||
| HER2-enriched | 26 (24.1) | 16 (28.6) | |
| Luminal A | 30 (27.8) | 10 (17.9) | |
| Luminal B | 28 (25.9) | 14 (25.0) | |
| Triple negative | 24 (22.2) | 16 (28.6) | |
| Grade | 0.021 | ||
| I | 8 (7.4) | 0 (0.0) | |
| II | 34 (31.5) | 12 (21.4) | |
| III | 66 (61.1) | 44 (78.6) | |
| Tumor volume (cm3) | 33.74 ± 52.14 | 49.04 ± 89.58 | 0.169 |
| TNM stage | 0.427 | ||
| I | 4 (3.7) | 3 (5.6) | |
| II | 34 (31.8) | 11 (20.4) | |
| III | 34 (31.8) | 22 (40.7) | |
| IV | 35 (32.7) | 18 (33.3) | |
| pT stage | 0.628 | ||
| T1 | 8 (7.4) | 5 (8.9) | |
| T2 | 60 (55.6) | 28 (50.0) | |
| T3 | 28 (25.9) | 19 (33.9) | |
| T4 | 12 (11.1) | 4 (7.1) | |
| pN stage | 0.136 | ||
| N0 | 27 (25.5) | 17 (32.1) | |
| N1 | 32 (30.2) | 7 (13.2) | |
| N2 | 20 (18.9) | 13 (24.5) | |
| N3 | 27 (25.5) | 16 (30.2) | |
| Distant metastasis | 0.860 | ||
| M0 | 72 (67.3) | 35 (64.8) | |
| M1 | 35 (32.7) | 19 (35.2) | |
| Axillary lymph node metastasis | 0.356 | ||
| Negative | 27 (25.2) | 18 (32.7) | |
| Positive | 80 (74.8) | 37 (67.3) | |
| Lymphovascular invasion | 1.000 | ||
| Negative | 36 (34.0) | 17 (32.7) | |
| Positive | 70 (66.0) | 35 (67.3) | |
| ER status | 0.249 | ||
| Negative | 50 (46.3) | 32 (57.1) | |
| Positive | 58 (53.7) | 24 (42.9) | |
| PR status | 0.249 | ||
| Negative | 50 (46.3) | 32 (57.1) | |
| Positive | 58 (53.7) | 24 (42.9) | |
| HER2 status | 0.742 | ||
| Negative | 54 (50.0) | 26 (46.4) | |
| Positive | 54 (50.0) | 30 (53.6) | |
| DCIS history | 0.331 | ||
| Absent | 23 (21.7) | 16 (29.6) | |
| Present | 83 (78.3) | 38 (70.4) | |
| Family history | 0.270 | ||
| No | 74 (81.3) | 32 (72.7) | |
| Yes | 17 (18.7) | 12 (27.3) | |
| Adjuvant chemotherapy | 0.598 | ||
| No | 2 (2.4) | 2 (4.9) | |
| Yes | 81 (97.6) | 39 (95.1) | |
| Adjuvant radiotherapy | 0.699 | ||
| No | 49 (59.0) | 26 (63.4) | |
| Yes | 34 (41.0) | 15 (36.6) | |
| Hormonal therapy | 0.252 | ||
| No | 38 (45.8) | 24 (58.5) | |
| Yes | 45 (54.2) | 17 (41.5) | |
| Immunotherapy | 1.000 | ||
| No | 79 (95.2) | 39 (95.1) | |
| Yes | 4 (4.8) | 2 (4.9) | |
| Ki-67 | 0.012 | ||
| Low | 71 (65.7) | 25 (44.6) | |
| High | 37 (34.3) | 31 (55.4) |
ER: estrogen receptor; PR: progesterone receptor; DCIS: ductal carcinoma in situ. p values in bold are those <0.05.